新型抗抑郁药物分子靶标研究进展-药学进展.pdfVIP

PROGRESS IN PHARMACEUTICAL SCIENCES 2016,40 8 :577-582 ( ) 577 新型抗抑郁药物分子靶标研究进展 1 2 2 1* 余旭奔 ， 杜贯涛 ，刘广军 ，洪浩 （1. 中国药科大学药学院药理系，江苏 南京 210009；2. 南京医科大学附属常州市第二人民医院药学部，江苏 常州 213003） [ 摘要 ] 抑郁症是一种严重的精神障碍疾病，其发病机制复杂。近年来随着对抑郁症发病机制的深入研究，发现了一些基于非单胺递质的 新型抗抑郁药物分子靶标。综述 N -甲基-D-天冬氨酸（NMDA）受体、促肾上腺皮质激素释放因子（CRF）受体、阿片受体、γ-氨基丁 酸 B(GABA ) 受体、乙酰胆碱受体等抗抑郁药物作用的新靶标及其相应分子机制研究进展，为开发高效、安全的抗抑郁症新药提供参考。 B [ 关键词 ] 抑郁症；NMDA 受体；CRF 受体；阿片受体；GABAB 受体；乙酰胆碱受体 [ 中图分类号 ] R964;R971.43 [ 文献标志码 ] A [ 文章编号 ] 1001-5094（2016）08-0577-06 Advances in Novel Molecular Targets for Antidepressants 1 2 2 1 YU Xubeng , DU Guantao , LIU Guangjun , HONG Hao (1. Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China; 2. Department of Pharmacy, Changzhou No. 2 People’s Hospital Affiliated with Nanjing Medical University, Changzhou 213003, China) [Abstract] Depression is a serious mental disorder with complex pathogenesis. In recent years, with in-depth study on the pathogenesis of depression, some novel molecular targets for antidepressants based on “monoaminergic hypothesis” were discovered. This paper reviewed these novel molecular targets such as NMDA receptor, CRF receptor 1, opioid receptor, GABAB receptor, and acetylcholine receptor, as well as their corresponding mechanisms, so as to provide references for developing highly effective and safe antidepressants. [Key words] depression; NMDA receptor; CRF receptor; opioid receptors; GABA receptor; acetylcholine receptor